Vaccine Safety

Antibody viability alludes to the capacity of immunizations to achieve the expected advantageous impacts on inoculated people in a characterized populace under perfect states of utilization. Antibody related hazard is the likelihood of an unfriendly or undesirable result happening and the seriousness of the subsequent damage to the strength of inoculated people in a characterized populace following vaccination with an immunization under perfect states of utilization.

  • Decreases in disease risks and increased attention on vaccine risks.
  • Factors Influencing Vaccine efficacy
  • Higher standard of safety is expected of vaccines
  • Patient and Public acceptance and perceptions
  • Post marketing surveillance of Vaccines
  • Public confidence in vaccine safety is critical
  • Vaccine Administration, Storage & Handling
  • Vaccine safety communication
  • Vaccine Safety Monitoring and Vaccine Pharmacovigilance
  • Vaccines generally healthy (vs. ill for drugs)

Related Conference of Vaccine Safety

November 19-20, 2025

6th International Conference on Vaccine Research

Tokyo, Japan
March 16-17, 2026

8th World Congress on Vaccine and Immunology

Paris, France
March 24-25, 2026

9th International Conference on Vaccines, Immunology and Clinical Trials

Paris, France
April 23-24, 2026

9th International Conference on Vaccines and Immunology

Paris, France
June 25-26, 2026

3rd Global Summit on Vaccines & Emerging Diseases

London, UK
August 27-28, 2026

7th International conference on Vaccines, Vaccination and Immunization

Paris, France
September 21-22, 2026

44th Euro Global Summit and Expo on Vaccines & Vaccination

Barcelona, Spain

Vaccine Safety Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in